| 谭夙雅,谢长生.CLDN18.2在晚期胃癌中的研究进展[J].肿瘤学杂志,2024,30(5):407-413. |
| CLDN18.2在晚期胃癌中的研究进展 |
| Research Progress on CLDN18.2 in Advanced Gastric Cancer |
| 投稿时间：2024-03-12 |
| DOI：10.11735/j.issn.1671-170X.2024.05.B009 |
|
 |
| 中文关键词: 紧密连接蛋白18.2 胃肿瘤 靶向治疗 |
| 英文关键词:CLDN18.2 gastric cancer targeted therapy |
| 基金项目: |
|
| 摘要点击次数: 229 |
| 全文下载次数: 132 |
| 中文摘要: |
| 摘 要：紧密连接蛋白18.2（CLDN18.2）表达于正常胃黏膜上皮细胞，并表达于胃癌、结肠癌、胰腺癌等实体瘤中，是目前消化系统肿瘤治疗的潜在靶点。针对CLDN18.2的靶向治疗主要包括单克隆抗体、嵌合抗原受体T细胞(chimeric antigen receptor T?鄄cell，CAR?鄄T)疗法、双特异性抗体和抗体偶联药物。目前已有多项靶向CLDN18.2的药物进入临床试验，其中以佐妥昔单抗（Zolbetuximab）进展最快。全文就CLDN18.2及其在晚期胃癌中的临床研究进展进行综述。 |
| 英文摘要: |
| Abstract： Tight junction protein CLDN18.2 is expressed in normal gastric mucosal epithelial cells and also in solid tumors such as gastric， colon， and pancreatic cancers， which is a potential therapeutic target for digestive system tumors. Various targeted therapies against CLDN18.2 have been designed， including monoclonal antibody， chimeric antigen receptor T-cell therapy (CAR-T)， bispecific antibody， and antibody-drug conjugate. Currently， clinical trials of several CLDN18.2-targeting drugs are ongoing， among which trials of Zolbetuximab have been advanced most. This paper provides a comprehensive review of research progress on CLDN18.2 and its applications in advanced gastric cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |